KYMR Kymera Therapeutics
- 35.090
- -3.270-8.52%
- 34.860
- -0.230-0.66%
Kymera Therapeutics News
Kymera Therapeutics to Present New Clinical Data From the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology Association (EHA) Annual
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Janux Therapeutics Inc (JANX) and Kymera Therapeutics (KYMR)
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using target
Earnings Call Summary | Kymera Therapeutics(KYMR.US) Q1 2024 Earnings Conference
The following is a summary of the Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript:Financial Performance:Kymera reported Q1 2024 revenue of $10.3 million, solely from its collaboratio
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Can Afford To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although software-as-a-service business Salesforce.com
Kymera Therapeutics Is Maintained at Outperform by Oppenheimer
Kymera Therapeutics Is Maintained at Outperform by Oppenheimer
Oppenheimer: The Kymera Therapeutics (KYMR.US) rating was maintained, and the target price was adjusted from better than the market to the better than the market rating, and the target price was adjusted from $53.00 to $52.00.
Oppenheimer: The Kymera Therapeutics (KYMR.US) rating was maintained, and the target price was adjusted from better than the market to the better than the market rating, and the target price was adjusted from $53.00 to $52.00.
Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53
Kymera Therapeutics (KYMR) has an average rating of outperform and price targets ranging from $30 to $112, according to analysts polled by Capital IQ.
Buy Rating Affirmed for Kymera Therapeutics Backed by Promising KT-253 Program Data and Upcoming ASCO Meeting Anticipation
Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript
Kymera Therapeutics Inc (KYMR) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises
Kymera Therapeutics (KYMR) reported a Q1 net loss Thursday of $0.69 per diluted share, narrower than a loss of $0.70 a year earlier. Analysts polled by Capital IQ expected a loss of $0.73. Collaborati
Kymera Therapeutics Q1 EPS $(0.69) Beats $(0.73) Estimate, Sales $10.29M Miss $13.69M Estimate
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.73) by 5.48 percent. This is a 1.43 percent increase over losses of $(
Press Release: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first
Kymera Therapeutics 1Q Loss/Shr 69c >KYMR
Kymera Therapeutics 1Q Loss/Shr 69c >KYMR
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein
Kymera Therapeutics Initiated at Outperform by Oppenheimer
Kymera Therapeutics Initiated at Outperform by Oppenheimer
Kymera Therapeutics (KYMR.US) was first covered by Oppenheimer, giving it an superior market rating, with a target price of $53.00.
Kymera Therapeutics (KYMR.US) was first covered by Oppenheimer, giving it an superior market rating, with a target price of $53.00.
Oppenheimer Initiates Coverage On Kymera Therapeutics With Outperform Rating, Announces Price Target of $53
Oppenheimer analyst Jeff Jones initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announces Price Target of $53.
Analysis
Price Target
No Data
